tbuckley/cabot-search huggingface dataset:
High-Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure
Authors: Stephen L. Seliger, Susie N. Hong, Robert H. Christenson, Richard Kronmal, Lori B. Daniels, Joao A.C. Lima, James A. de Lemos, Alain Bertoni, Christopher R. deFilippi
Journal: Circulation (2017)

Although small elevations of high-sensitive cardiac troponin T (hs-cTnT) are associated with incident heart failure (HF) in the general population, the underlying mechanisms are not well defined. Evaluating the association of hs-cTnT with replacement fibrosis and progression of structural heart disease before symptoms is fundamental to understanding the potential of this biomarker in a HF prevention strategy.We measured hs-cTnT at baseline among 4986 participants in MESA (Multi-Ethnic Study of Atherosclerosis), a cohort initially free of overt cardiovascular disease (CVD). Cardiac magnetic resonance imaging was performed at baseline. Repeat cardiac magnetic resonance was performed 10 years later among 2831 participants who remained free of interim CVD events; of these, 1723 received gadolinium-enhanced cardiac magnetic resonance for characterization of replacement fibrosis by late gadolinium enhancement. Progression of subclinical CVD was defined by 10-year change in left ventricular structure and function. Associations of hs-cTnT with incident HF, CV-related mortality, and coronary heart disease were estimated using Cox regression models.Late gadolinium enhancement for replacement fibrosis was detectable in 6.3% participants without interim CVD events by follow-up cardiac magnetic resonance. A graded association was observed between higher baseline hs-cTnT categories and late gadolinium enhancement (≥7.42 ng/L versus <limit of detection [<3 ng/L]; adjusted odds ratio, 2.87; 95% confidence interval, 1.38-5.94). Higher hs-cTnT was also associated with a greater probability of an increase in LV mass >12% (highest category versus <limit of detection; odds ratio, 1.50; 95% confidence interval, 1.09-2.07), but not with decline in left ventricular ejection fraction. The risk of incident HF was greater for higher hs-cTnT (≥8.81 ng/L versus <limit of detection; adjusted hazards ratio, 5.59; 95% CI, 2.97-10.68).hs-cTnT levels are associated with replacement fibrosis and progressive changes in left ventricular structure in CVD-free adults, findings that may precede HF symptoms by years. Minor elevations of hs-cTnT may represent a biochemical signature of early subclinical cardiac disease, providing an opportunity for targeted preventive interventions.
Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.
Authors: Daniel W. Sherbenou, Oliver J. Hantschel, Lalita Turaga, Ines Kaupe Mag, Stephanie Willis, Thomas Bumm, Richard D. Press, Giulio Superti-Furga, Brian J. Druker, Michael W. Deininger
Journal: Blood (2007)
Noninvasive Prediction of Acute Graft-Verus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation by Circulating miRNA Profiling
Authors: Cristiana Carniti, Silvia Gimondi, Davide Lucini, Jacopo Mariotti, Anisa Bermema, Antonio Vendramin, Mara Morelli, Chiara Formica, Paolo Corradini
Journal: Blood (2011)
Proliferation of CD8+ T-Cells Specific for CMV and EBV in Response to TCR Mediated Recognition of Cognate Antigen Is Inhibited by Imatinib in a Dose-Dependent Manner.
Authors: Ruth Seggewiss, Karin Lore, Elisabeth Greiner, Magnus K. Magnusson, David A. Price, Daniel C. Douek, Cynthia E. Dunbar, Adrian Wiestner
Journal: Blood (2004)
The G Protein-Coupled Receptor cysLT1 Mediates Gi Protein-Dependent Chemotaxis and Adhesion of CD34+ Cells in Vitro Similar to CXCR4, but Not Progenitor Mobilization in Vivo.
Authors: Adriana Drost, Lena Jaggy, Lothar Kanz, Robert Möhle
Journal: Blood (2008)
MicroRNA-Ago2 Complex in Mature Human Red Blood Cells.
Authors: Tsukuru Umemura, Yuka Tanaka, Megumi Fujisaki, Shizuka Masaki, Hiromichi Shiotsu, Kanitta Srinoun, Suthat Fucharoen, Yasunobu Abe, Hisako Ichihara, Hiroyuki Toh, Hajime Hisaeda
Journal: Blood (2009)
Firestone &amp; Scholl conflate two distinct issues
Authors: Ryan Ogilvie, Peter Carruthers
Journal: Behavioral and Brain Sciences (2016)

Firestone & Scholl (F&S) seem to believe that the viability of a distinction between perception and cognition depends on perception being encapsulated from top-down information. We criticize this assumption and argue that top-down effects can leave the distinction between perception and cognition fully intact. Individuating the visual system is one thing; the question of encapsulation is quite another.
Impact of a Venous Thromboembolism Prophylaxis “Smart Orderset”: Improved Compliance, Fewer Events
Authors: Amer M. Zeidan, Michael B. Streiff, Syed-Rafay Ahmed, Peggy S Kraus, Deborah Hobson, Paula B Horn, Kenneth Shermock, Gabriel Tinoco, Elliott R Haut
Journal: Blood (2011)
EPIG-06ATRX DEFICIENCY PROMOTES MIGRATORY BEHAVIOR IN GLIOMA CELLS OF ORIGIN BY DYSREGULATING GENOME-WIDE CHROMATIN ACCESSIBILITY AND MODULATING TRANSCRIPTIONAL PROGRAMS
Authors: Carla Danussi, Promita Bose, Prasanna Parthasarathy, Sevin Turcan, David Picketts, Timothy Chan, Jason Huse
Journal: Neuro-Oncology (2015)

Comprehensive genomic profiling in cancer continues to reveal frequent alterations in epigenetic regulators, firmly implicating chromatin biology in the oncogenic process. We and others recently found that inactivating mutations in the SWI/SNF family member ATRX represent defining molecular alterations in diffusely infiltrating gliomas, where they invariably pair with mutations in TP53 and IDH1/2. A number of studies have linked ATRX deficiency to a wide spectrum of physiological dysfunction, including aberrant gene regulation, abnormal telomere maintenance, genomic instability, and aneuploidy. Nevertheless, the molecular mechanism(s) by which ATRX deficiency promotes oncogenesis are still largely unestablished. To understand the role of Atrx loss-of-function mutations in gliomagenesis, we inactivated Atrx in Tp53-/- murine neuroepithelial progenitor cells (NPCs), which have been implicated as potential glioma cells of origin by several prior studies. Interestingly, Atrx loss induced NPCs to stop growing as neurospheres and adopt an adherent phenotype, while also exhibiting significantly increased cellular motility by transwell migration assay, the latter an established pathogenic feature of diffusely infiltrating gliomas. These phenotypes correlated with altered gene expression profiles involving molecular networks implicated in development, regulation of signal transduction, and cellular motility and invasion. Integrating these transcriptional changes with shifts in chromatin accessibility occurring with Atrx deficiency and genome-wide Atrx distribution, as determined by ChIP-seq, revealed highly significant spatial correlations between differentially expressed genes, regions of altered chromatin compaction, and genomic sites normally occupied by Atrx. Taken together, these findings demonstrate that Atrx deficiency induces widespread disruptions in chromatin organization, which in turn lead to dramatic shifts in gene expression and acquisition of disease-relevant phenotypes in putative glioma cells of origin. We are now in the process of identifying and characterizing the precise transcriptional and epigenetic events mediating the acquisition of Atrx-dependent behaviors in NPCs.
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy (NCT) and analysis of survival outcome.
Authors: Napa Parinyanitikul, Xiudong Lei, Mariana Chavez-Mac Gregor, Elizabeth Ann Mittendorf, Jennifer Keating Litton, Wendy A. Woodward, Hong Zhang, Gabriel N. Hortobagyi, Ana M. Gonzalez-Angulo
Journal: Journal of Clinical Oncology (2013)

48 Background: Treatment and prognosis of breast cancer is determined by tumor subtype. Tumor heterogeneity and lack of stability in ER, PR and HER2 has been described. We evaluated the changes receptor status between primary and residual disease after NCT and its association with outcome. Methods: 398 women with known ER, PR and HER2 status in primary and residual disease were identified. Patients were classified as no receptor change vs. any receptor change. For ER and PR we explored absolute percent changes. Descriptive statistics were used. Kaplan-Meier method was used to estimate overall (OS) and recurrence-free (RFS) survival. Cox proportional models were fit to determine the association of receptor status changes with outcomes after adjustment for patient and disease characteristics. Results: From the 398 patients, 162 (40.7%) had a change in at least one biomarker. Twenty-three (10.9%) of the 211 ER-positive tumors changed to ER-negative and 39 (20.8%) of the 187 ER-negative tumors changed to ER-positive. Fifty-seven (35.2%) of the 162 PR-positive tumors changed to PR-negative and 28 (11.9%) of the 235 PR-negative tumors changed to PR-positive. Lastly, 29 (40%) of the 72 HER2-positive tumors changed to HER2-negative and among the 35 trastuzumab-treated patients, 16 (45.7%) had HER2 status changed. At a median follow up of 40 months, 128 women (32%) had died, and 167 (41.8%) had experienced a recurrence. Five-year OS estimates were 73% and 63% for patients with or without any receptor change, (P=0.07); 5-year RFS estimates were 63% and 48% for patients with or without any receptor change, (P=0.003). Among patients with baseline ER-positive tumors, 5-year OS estimates was 73% and 87% (P=0.03), and the 5-year RFS estimates was 59% and 71% (P=0.03) for those whose absolute ER percent decrease was less than 20% or more than 20%, respectively. A change in any receptor was associated with better RFS (HR: 0.63, 95% CI 0.44-0.9) but not with OS, (HR: 0.79, 95% CI 0.53-1.18). Conclusions: Changes in ER, PR and HER2 status between the primary and the residual disease after neoadjuvant chemotherapy are frequent. In this study, a change in biomarker status was associated with significant improved RFS.
Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression
Authors: Elisabeth Schramm, Levente Kriston, Ingo Zobel, Josef Bailer, Katrin Wambach, Matthias Backenstrass, Jan Philipp Klein, Dieter Schoepf, Knut Schnell, Antje Gumz, Paul Bausch, Thomas Fangmeier, Ramona Meister, Mathias Berger, Martin Hautzinger, Martin Härter
Journal: JAMA Psychiatry (2017)

Chronic depression is a highly prevalent and disabling disorder. There is a recognized need to assess the value of long-term disorder-specific psychotherapy.To evaluate the efficacy of the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) compared with that of nonspecific supportive psychotherapy (SP).A prospective, multicenter, evaluator-blinded, randomized clinical trial was conducted among adult outpatients with early-onset chronic depression who were not taking antidepressant medication. Patients were recruited between March 5, 2010, and October 16, 2012; the last patient finished treatment on October 14, 2013. Data analysis was conducted from March 5, 2014, to October 27, 2016.The treatment included 24 sessions of CBASP or SP for 20 weeks in the acute phase, followed by 8 continuation sessions during the next 28 weeks.The primary outcome was symptom severity after 20 weeks (blinded observer ratings) as assessed by the 24-item Hamilton Rating Scale for Depression (HRSD-24). Secondary outcomes were rates of response (reduction in HRSD-24 score of ≥50% from baseline) and remission (HRSD-24 score ≤8), as well as self-assessed ratings of depression, global functioning, and quality of life.Among 622 patients assessed for eligibility, 268 were randomized: 137 to CBASP (96 women [70.1%] and 41 men [29.9%]; mean [SD] age, 44.7 [12.1] years) and 131 to SP (81 women [61.8%] and 50 men [38.2%]; mean [SD] age, 45.2 [11.6] years). The mean (SD) baseline HRSD-24 scores of 27.15 (5.49) in the CBASP group and 27.05 (5.74) in the SP group improved to 17.19 (10.01) and 20.39 (9.65), respectively, after 20 weeks, with a significant adjusted mean difference of -2.51 (95% CI, -4.16 to -0.86; P = .003) and a Cohen d of 0.31 in favor of CBASP. After 48 weeks, the HRSD-24 mean (SD) scores were 14.00 (9.72) for CBASP and 16.49 (9.96) for SP, with an adjusted difference of -3.13 (95% CI, -5.01 to -1.25; P = .001) and a Cohen d of 0.39. Patients undergoing CBASP were more likely to reach response (48 of 124 [38.7%] vs 27 of 111 [24.3%]; adjusted odds ratio, 2.02; 95% CI, 1.09 to 3.73; P = .03) or remission (27 of 124 [21.8%] vs 14 of 111 [12.6%]; adjusted odds ratio, 3.55; 95% CI, 1.61 to 7.85; P = .002) after 20 weeks. Patients undergoing CBASP showed significant advantages in most other secondary outcomes.Highly structured specific psychotherapy was moderately more effective than nonspecific therapy in outpatients with early-onset chronic depression who were not taking antidepressant medication. Adding an extended phase to acute psychotherapy seems promising in this population.clinicaltrials.gov Identifier: NCT00970437.
The Combination of the EBMT Score and the HCT-CI Is Not Better Than the HCT-CI Alone in the Prediction of NRM and OS in Patients Undergoing Allogeneic Hematopoietic Transplantation with Reduced-Toxicity Conditioning
Authors: Pere Barba, David Valcarcel, Lucía López-Corral, Francesc fernandez-Aviles, Rodrigo Martino, Monica Cabrero, Montserrat Rovira, jose Luis Pinana, Salut Brunet, Enric Carreras, maria Dolores Caballero, Jorge Sierra
Journal: Blood (2012)
Clinical characteristics and prognosis of non-B, non-C hepatocellular carcinoma: The impact of patient sex on disease-free survival - A retrospective cohort study
Authors: Masakazu Hashimoto, Hirotaka Tashiro, Tsuyoshi Kobayashi, Shintaro Kuroda, Michinori Hamaoka, Hideki Ohdan
Journal: International Journal of Surgery (2017)
高レベルの飽和極長鎖脂肪酸(C26:0)は冠状動脈疾患に対する新しい独立した危険マーカーである
Authors: Hiki Makoto, Miyazaki Tetsuro, Kume Atsumi, Kitamura Yohei, Oshida Kyoichi, Yanagisawa Notake, Takizawa Hirotaka, Fujii Kiyotaka, Kiyanagi Takashi, Sumiyoshi Katsuhiko, Mokuno Hiroshi, Shimada Kazunori, Daida Hiroyuki
Journal: Circulation (2007)
Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.
Authors: Lynn R Goldin, Mark C Lanasa, Susan L Slager, Sara S Strom, Nicola J Camp, James R Cerhan, Logan G Spector, Jose F Leis, Vicki A. Morrison, Laura Z. Rassenti, Kari Rabe, Laura Fontaine, Sallie D Allgood, Fatima Abbasi, Neil E. Kay, Timothy G Call, Curtis A Hanson, J. Brice Weinberg, Gerald E Marti, Neil E Caporaso
Journal: Blood (2009)
Mesenchymal stem cells: key players in cancer progression
Authors: Sarah M. Ridge, Francis J. Sullivan, Sharon A. Glynn
Journal: Molecular Cancer (2017)

Tumour progression is dependent on the interaction between tumour cells and cells of the surrounding microenvironment. The tumour is a dynamic milieu consisting of various cell types such as endothelial cells, fibroblasts, cells of the immune system and mesenchymal stem cells (MSCs). MSCs are multipotent stromal cells that are known to reside in various areas such as the bone marrow, fat and dental pulp. MSCs have been found to migrate towards inflammatory sites and studies have shown that they also migrate towards and incorporate into the tumour. The key question is how they interact there. MSCs may interact with tumour cells through paracrine signalling. On the other hand, MSCs have the capacity to differentiate to various cell types such as osteocytes, chondrocytes and adipocytes and it is possible that MSCs differentiate at the site of the tumour. More recently it has been shown that cross-talk between tumour cells and MSCs has been shown to increase metastatic potential and promote epithelial-to-mesenchymal transition. This review will focus on the role of MSCs in tumour development at various stages of progression from growth of the primary tumour to the establishment of distant metastasis.
Transgenesis of Multipotent Adult Progenitor Cells (MAPC) with Sleeping Beauty Transposons to Determine MAPC Homing and Persistence in Real-Time In Vivo.
Authors: Jakub Tolar, Mark Osborn, Scott Bell, Lily Xia, Megan Riddle, Angela Panoskaltsis-Mortari, Scott McIvor, Yant R. Stephen, Mark A. Kay, Christopher H. Contag, Catherine M. Verfaillie, Bruce R. Blazar
Journal: Blood (2004)
Inflammatory breast cancer in Manizales from a developing country like Colombia
Authors: J. A. Chacon Cardona, C. R. Villegas Mejia, T. Sanchez Villegas, J. P. Cardona Arcila
Journal: Journal of Clinical Oncology (2008)

11573 Background: Inflammatory breast cancer is one of the worst cancers in the world and for developing countries it seems to have the same prognosis; we studied this specific group for knowing its behavior in the Instituto Oncologico ION S.A., Manizales. Methods: It begins with a retrospective analysis from our cancer records in order to extract this specific breast cancer population. Results: The group accrued 888 breast cancer patients from January 1995 to December 2006 with 52 (5.85%); 100% female; median age 55 (range 25–93 SD:12.743); urban area 100%; clinical symptom was mass (71%), best diagnoses method was test by themselves (93%), second neoplasia in 4% with contralateral breast cancer (100%), ductal carcinoma (98%), RE(+) 23%, RP(+) 19% and HER(+) 6% in only 10% of the patients, invasion lymph-vascular (+) 43%, MRM surgery 58%, conservative surgery 8%, mean resected nodes 11 and mean positive resected nodes 7, familiar first degree antecedent 4%, postmenopausal stage 60%, right breast 40%, CSE localization 31%, initial chemotherapy (QT) scheme FAC 60%, AC 23% CMF 4%; 27% changed initial QT because of bad pathologic response in 18% and without clinical response with initial QT 10%; radiotherapy (RT) boost 8%; mean tamoxifen therapy 12 months (range 1 to 84 months SD: 20.087) and 17% patients received a second hormone therapy because of relapse; general complications 14% like hematologic (55%); neoadjuvant treatment 64% with QT (94%) and adjuvant treatment 58% based of QT and RT (80%); global relapse (40%) with bone (28%), scar (19%), lung (10%), skin (13%), CNS (16%) and liver (3%) mean follow-up of 34 months (SD: 27.247) and overall survival by Kaplan-Meier at 5 years for breast cancer was 48.4% (95% CI: 57.2–72.2). Conclusions: This is the inflammatory breast cancer group in our population and we think that it is not different from other specific results from other cancer groups. No significant financial relationships to disclose.
IL-10 Promoter Region -592A/C Genotype Increases the Risk of Multiple Myeloma in Japanese Patients.
Authors: Takayuki Saitoh, Tetsuhiro Kasamatsu, Hitomi Matsuoka, Miyuki Endoh, Madoka Inoue, Arito Yamane, Hiroyuki Irisawa, Hiroshi Handa, Takafumi Matsushima, Norifumi Tsukamoto, Masamitsu Karasawa, Hatsue Ogawara, Yoshihisa Nojima, Hirokazu Murakami
Journal: Blood (2006)
Endoscopic treatment of a sigmoid perforation caused by an ingested fish bone
Authors: Congcheng Fang, Liping Ye, Xinli Mao, Jinshun Zhang
Journal: Endoscopy (2017)

A 68-year-old man was admitted with severe abdominal pain since the previous day. His physical examination was unremarkable, except for mild lower abdominal tenderness without rebound tenderness. Laboratory tests showed he had an elevated white blood cell count (11 800 cells/µL) and increased C-reactive protein (CRP) level (105 mg/L). A computed tomography (CT) scan revealed a radiodense linear foreign body that was extending transmurally through the wall of the sigmoid colon ([Fig. 1]). Colonoscopy demonstrated a fish bone stuck in the sigmoid colon wall ([Fig. 2]).
Cap on lawyers’ fees for minor negligence claims could save NHS £45m a year
Authors: Clare Dyer
Journal: BMJ (2017)

Lawyers whose clients win compensation between £1000 and £25 000 (€29 000; $31 000) for clinical errors will have the costs they can recover from the NHS capped, under proposals from the Department of Health for England.1

The move is aimed at saving legal costs in clinical negligence claims of lower value, where costs can often dwarf the compensation received.

The Medical Defence Union, which indemnifies doctors against legal claims, said that the proposal did not go far enough and argued that the health department should have gone ahead with an earlier plan to cap …
Optimal Outcomes after Second Hematopoietic Stem Cell Transplantation in Patients with Thalassemia Recurrence Following Graft Failure/Rejection of the First Graft
Authors: Javid Gaziev, Katia Paciaroni, Gioia De Angelis, Antonella Isgro, Marco Marziali, Marco Andreani, Cecilia Alfieri, Michela Ribersani, Guido Lucarelli
Journal: Blood (2016)
Noncovalent Bonding of RGD and YIGSR to an Electrospun Poly(ε‐Caprolactone) Conduit through Peptide Self‐Assembly to Synergistically Promote Sciatic Nerve Regeneration in Rats
Authors: Lei Zhu, Kai Wang, Teng Ma, Liangliang Huang, Bing Xia, Shu Zhu, Yafeng Yang, Zhongyang Liu, Xin Quan, Kai Luo, Deling Kong, Jinghui Huang, Zhuojing Luo
Journal: Advanced Healthcare Materials (2017)

The nerve conduit with biofunctionalities can regulate neurite outgrowth, as well as the migration, proliferation, and myelination activity of Schwann cells. In the present study, polycaprolactone (PCL) conduits are coated with Naphthalene-phenylalanine-phenylalanine-glycine-arginine-glycine-aspartic (Nap-FFGRGD) and Naphthalene-phenylalanine-phenylalanine-glycine-cysteine-aspartic-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine (Nap-FFGCDPGYIGSR) by self-assembly. In vitro studies demonstrate that arginine-glycine-aspartic (RGD) and tyrosine-isoleucine-glycine-serine-arginine (YIGSR) are capable of synergistically enhancing the ability of PCL to support the adhesion and proliferation of Schwann cells, as well as increasing neurite outgrowth from dorsal root ganglions explants. This synergistic effect may occur via the activation of both the phosphoinositide 3-kinase/protein kinase B and mitogen-activated protein kinase/extracellular signal-regulated protein kinase pathways. RGD/YIGSR modifications demonstrate beneficial effects across a 15 mm sciatic nerve gap in axonal regeneration and functional recovery. In addition, increased vascularization is observed in the RGD/YIGSR-PCL group, which might contribute to their beneficial effects on nerve regeneration. These findings indicate the potential of the RGD/YIGSR-PCL conduit to promote axonal regeneration and functional recovery, making the RGD/YIGSR-PCL conduit an attractive candidate for the treatment of a critical nerve defect.
The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study
Authors: Ioannis Baltathakis, Evangelos Terpos, Sosana Delimpasi, Konstantinos Liapis, Fotios Panitsas, Efstathios Kastritis, Anna Christoforidou, Anastasia Pouli, Konstantinos Tsatalas, Meletios A. Dimopoulos, Nikolaos Harhalakis
Journal: Blood (2010)
Third Autologous Salvage Transplant at Late Myeloma Relapse Is Associated with Favourable Overall Survival and Contributes to Improvement of Exhausted Bone Marrow Function
Authors: Susanne Strifler, Inken Hilgendorf, Martina Kleber, Christoph Röllig, Lars-Olof Mügge, Maria-Veronica Teleanu, Brigitte Kragl, Hermann Einsele, Stefan Knop
Journal: Blood (2014)
Task demand not so damning: Improved techniques that mitigate demand in studies that support top-down effects
Authors: Emily Balcetis, Shana Cole
Journal: Behavioral and Brain Sciences (2016)

Firestone & Scholl's (F&S's) techniques to combat task demand by manipulating expectations and offering alternative cover stories are fundamentally flawed because they introduce new forms of demand. We review five superior techniques to mitigate demand used in confirmatory studies of top-down effects. We encourage researchers to apply the same standards when evaluating evidence on both sides of the debate.